LEON : Enabling Nano Now

Enhancing Small Molecule Solubility: Advancing Liposomal Drug Delivery with FR-JET®

  • News

We’re excited to share a case study on our successful collaboration with Glatt, highlighting how our FR-JET® technology enables superior liposomal formulation.

Key insights from our feasibility study:

  • Successfully formulated naproxen-loaded liposomes using various lipid compositions, highlighting new drug delivery possibilities.
  • Achieved liposome sizes ≤150 nm and a PDI of ≤0.14, demonstrating robust and efficient formulation screening.
  • Showcased FR-JET® technology’s potential to streamline liposomal research, and optimize scale-up manufacturing for future applications.

 

READ MORE HERE

About LEON

Based in Planegg/Munich, leon-nanodrugs GmbH is a pharmatech company specializing in the development and commercialization of equipment for the encapsulation of genetic material and other pharmaceutical active substances into nanoparticles, such as lipid nanoparticles (LNPs).

The company leverages its proprietary FR-JET®  technology to build innovative solutions. Its equipment portfolio includes NANOscreen® for formulation screening, NANOlab® for process development, as well as NANOme® and NANOus® for GMP manufacture. These systems are suitable for both individualized scales and commercial production, and the company further supports its clients by offering formulation and process development services.

LEON’s platform aims to empower pharmaceutical companies, small biotech, research institutes, and CDMOs to capitalize on advancements in advanced therapies.

For general information and enquiries please email info@leon-nanodrugs.com